ArBlast was established in December 2005. Using the collagen sheet obtained by processing the human amniotic membrane, it is a regenerative medicine venture that regenerates various tissues.

At present, ArBlast is engaged in the development of the refined collagen sheet derived from human amnion which is made from refining the human amnion and using this sheet as the basement membrane, cultured corneal epithelial cell sheet and cultured corneal endothelial sheet are being developed. The collagen sheet derived from human amnion has diverse immunological characteristics, and at present it is impossible to synthesize substitute collagen sheets. Furthermore, the amniotic membrane does not include blood vessel elements, making it possible to reduce rejection after transplant. This is a big benefit of the sheet. The sheet is suitable as culture basement membrane for different types of tissue. Even for independent use, its application in medical treatment is being considered.

ArBlast intends to make full utilization of the properties of the collagen sheet, and going beyond the ophthalmological application that is being developed at present, the company seeks to become a global concern that undertakes tissue regeneration in other areas.

Message from CEO (Japanese)